biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
05:35 One-time immune cell therapy held MS steady in early trial, maker says✦05:44 Lilly moves a Zepbound add-on that boosted weight loss into big trials✦05:43 Own tumor immune cells plus Keytruda made melanoma vanish on scans in 29%✦05:39 DNA of 8 long-lived bat species ties virus defenses to long life✦05:36 Cholesterol pills cut heart problems in healthy older people, not dementia✦05:32 One-time gene therapy for Duchenne muscle disease met its main trial goal✦05:40 Adding a second immune drug cut death risk 58% in deadly lung cancer trial✦05:27 Custom-made melanoma vaccine cut risk of return or death 42% in big trial✦05:35 One-time immune cell therapy held MS steady in early trial, maker says✦05:44 Lilly moves a Zepbound add-on that boosted weight loss into big trials✦05:43 Own tumor immune cells plus Keytruda made melanoma vanish on scans in 29%✦05:39 DNA of 8 long-lived bat species ties virus defenses to long life✦05:36 Cholesterol pills cut heart problems in healthy older people, not dementia✦05:32 One-time gene therapy for Duchenne muscle disease met its main trial goal✦05:40 Adding a second immune drug cut death risk 58% in deadly lung cancer trial✦05:27 Custom-made melanoma vaccine cut risk of return or death 42% in big trial
← All story threadsSTORY THREAD

Amgen's Imdelltra for small cell lung cancer.

1 report so far. New developments are added to this thread as they happen.

  1. Oct 24, 2026
    ADDED TO IMFINZI, CUTS DEATH RISK 58% IN BIG TRIALControlled trial · 563 people

    Adding a second immune drug cut death risk 58% in deadly lung cancer trial

    In a 563-person trial, people with advanced small cell lung cancer who got Amgen's Imdelltra on top of Imfinzi lived a median 21.1 months, against 12.7 months on Imfinzi alone.